NCT02367976 is a Phase 3 clinical trial of rhprouk in STEMI, sponsored by Suzhou RxD Biopharmaceutical Co., Ltd.

Who is sponsoring NCT02367976?

NCT02367976 is sponsored by Suzhou RxD Biopharmaceutical Co., Ltd.

What drugs are being tested in NCT02367976?

Interventions in NCT02367976: rhprouk.

Is NCT02367976 still recruiting?

NCT02367976 is currently status unknown. Last updated 24 February 2015.

Last reviewed 2015-02-24 · How we verify

NCT02367976

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase III Study to Research the Efficacy and Safety on Prouk for ST Elevated Mycadial Infarction Patients in China

Status unknown Phase 3 Last updated 24 February 2015

What this trial tests

Phase 3 trial testing rhprouk in STEMI in 450 participants. Status unknown.

Timeline

1 January 2015

Primary endpoint
1 December 2016

1 December 2017

Quick facts

Lead sponsor	Suzhou RxD Biopharmaceutical Co., Ltd
Phase	Phase 3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	450
Start date	1 January 2015
Primary completion	1 December 2016
Estimated completion	1 December 2017
Sites	1 location across China

Drugs / interventions tested

rhprouk — full drug profile →

Conditions studied

STEMI — all drugs for STEMI →

Sponsor

Suzhou RxD Biopharmaceutical Co., Ltd — full company profile →

Who can join

Adults 18 to 75, any sex, with STEMI. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

To compare the percentage of STEMI patients achieving the recanalization of Coronary between the two arms
Time frame: 90 minutes after administrative of active/comparator

Sponsor's own description

The purpose of the study is to evaluate the efficacy and safety of rh-prouk as pharmacoinvasive therapy on those ST Elevated Myocardial Infarctions patients, it is designed as a multicenter, active controlled, single blinded study. The primary endpoint is to assess the coronary recanalization 90 minutes after thrombolysis. The secondary endpoint is to evaluate the mortality rate at day 30.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for STEMI

Currently open trials in the same condition.

NCT06966674 — No-Reflow in Patients With STEMI After Intracoronary Tirofiban After Opening of the Track · NA · recruiting
NCT06678074 — Pilot Study of IC14 (Atibuclimab), an Anti-CD14 Monoclonal Antibody, to Treat STEMI · Phase 1, PHASE2 · active not recruiting
NCT07055152 — Retinal OCTA for Microvascular Dysfunction Evaluation and Outcome Prediction in MINOCA Patients · recruiting
NCT06528821 — AI-Powered ECG Detecting Culprit Vessel Blood Flow Abnormality in ACS · active not recruiting
NCT07026708 — TIRANA-ACS: A Prospective Registry Study for the Targeted Investigation of Residual Inflammation After Non-ST/ ST Elevat · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02367976 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Suzhou RxD Biopharmaceutical Co., Ltd
Last refreshed: 24 February 2015

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02367976.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing